New research presented at the Endocrine Society’s annual meeting (ENDO2019) in the US this week suggests that testosterone treatment may be beneficial for men with hypogonadism and obesity.
The 10-year observational study included 805 men with hypogonadism, of whom 462 (57.4%) were obese. Of patients with obesity, 273 received testosterone therapy with testosterone undecanoate injections (1,000 mg/12 weeks; T-group) while 189 served as controls.
Over 10 years, the testosterone-treated men lost 20.3 per cent of their baseline weight (22.9 kg) and waist circumference dropped by 12.5 cm. Body mass index (BMI) decreased by 7.3 kg/m2, and waist-to-height ratio decreased by 0.07.
By contrast, the untreated men gained 3.9 per cent of their baseline weight (3.2 kg), and waist size increased by 4.6 cm. In this group, BMI increased by 0.9 kg/m2 and waist-to-height ratio increased by 0.03.
During this time, 12 (4.4%) men in the testosterone group died, while in the untreated control group, 57 deaths (30.2%), 47 myocardial infarctions (24.9%) and 44 strokes (23.3%) occurred.
The authors said the findings suggest testosterone should be measured in obese men and testosterone treatment offered if indicated.